IFP Advisors’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
– Sell
-21
Closed -$1.02K – 3175
2019
Q3
$1K Buy
+21
New +$1.51K ﹤0.01% 2963
2019
Q1
– Sell
-21
Closed -$3K – 3579
2018
Q4
$3K Hold
21
– – ﹤0.01% 3085
2018
Q3
$5K Hold
21
– – ﹤0.01% 3241
2018
Q2
$5K Hold
21
– – ﹤0.01% 3298
2018
Q1
$6K Hold
21
– – ﹤0.01% 3108
2017
Q4
$6K Sell
21
-1
-5% -$329 ﹤0.01% 3154
2017
Q3
$8K Sell
22
-470
-96% -$167K ﹤0.01% 3181
2017
Q2
$179K Buy
492
+471
+2,243% +$141K 0.01% 1192
2017
Q1
$6K Hold
21
– – ﹤0.01% 3234
2016
Q4
$5K Sell
21
-14
-40% -$2.81K ﹤0.01% 3337
2016
Q3
$8K Buy
35
+14
+67% +$2.91K ﹤0.01% 3000
2016
Q2
$4K Buy
+21
New +$9.7K ﹤0.01% 3281

Other funds holding DMK

IFP Advisors's DMK Position: Q4 2019 in Review

IFP Advisors sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q4 2019, closing a stake of 21 shares — an estimated $1.02K sold.

IFP Advisors first reported a position in DMK in Q2 2016 and held it in 12 quarters. The position peaked at $179K in Q2 2017. 38 funds tracked by Wall St. Rank hold DMK as of Q4 2019.

  • IFP Advisors reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q4 2019 after selling out during the quarter.
  • IFP Advisors sold 21 DMK Pharmaceuticals Corporation Common Stock shares in Q4 2019, an estimated $1.02K.
  • IFP Advisors first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q2 2016 and held it in 12 quarters.
  • IFP Advisors's DMK Pharmaceuticals Corporation Common Stock position peaked at $179K in Q2 2017.
  • 38 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q4 2019.

Based on IFP Advisors's 13F filing for Q4 2019, filed 17 Jan 2020.